$ENDP Are Earnings Prospects Improving For Loss-Making Endo International plc’s (NASDAQ:ENDP)?
After looking at Endo International plc’s (NASDAQ:ENDP) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess this against the most recent figures. As a long term investor, I pay close attention to earnings trend, rather than the figures published at one point in time. I also compare against an industry benchmark to check whether Endo International’s performance has been impacted by industry movements. In this article I briefly touch on my key findings. Check out our latest analysis for Endo International
Did ENDP’s recent earnings growth beat the long-term trend and the industry?
For the most up-to-date info, I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. This method allows me to assess different stocks on a more comparable basis, using the most relevant data points. For Endo International, its latest trailing-twelve-month earnings is -US$1.23B, which, relative to the prior year’s figure, has become less negative. Since these figures are relatively short-term thinking, I’ve computed an annualized five-year value for Endo International’s net income, which stands at -US$768.78M. This suggests that, Endo International has historically performed better than recently, despite the fact that it seems like earnings are now heading back in the right direction again.
We can further evaluate Endo International’s loss by looking at what the industry has been experiencing over the past few years. Each year, for the past half a decade Endo International’s top-line has risen by a mere 7.89%, on average. The company’s inability to breakeven has been aided by the relatively flat top-line in the past. Viewing growth from a sector-level, the US pharmaceuticals industry has been growing its average earnings by double-digit 13.53% in the prior year, and a more subdued 9.89% over the past five years. This shows that, though Endo International is currently running a loss, it may have gained from industry tailwinds, moving earnings towards to right direction.
What does this mean?
Though Endo International’s past data is helpful, it is only one aspect of my investment thesis. Companies that incur net loss is always hard to forecast what will happen in the future and when. The most insightful step is to examine company-specific issues Endo International may be facing and whether management guidance has dependably been met in the past. You should continue to research Endo International to get a more holistic view of the stock by looking at:
Future Outlook: What are well-informed industry analysts predicting for ENDP’s future growth? Take a look at our free research report of analyst consensus for ENDP’s outlook.
Financial Health: Is ENDP’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
After looking at Endo International plc’s (NASDAQ:ENDP) latest earnings announcement (31 December 2017), I found it useful to revisit the company’s performance in the past couple of years and assess this against the most recent figures. As a long term investor, I pay close attention to earnings trend, rather than the figures published at one point in time. I also compare against an industry benchmark to check whether Endo International’s performance has been impacted by industry movements. In this article I briefly touch on my key findings. Check out our latest analysis for Endo International
Did ENDP’s recent earnings growth beat the long-term trend and the industry?
For the most up-to-date info, I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. This method allows me to assess different stocks on a more comparable basis, using the most relevant data points. For Endo International, its latest trailing-twelve-month earnings is -US$1.23B, which, relative to the prior year’s figure, has become less negative. Since these figures are relatively short-term thinking, I’ve computed an annualized five-year value for Endo International’s net income, which stands at -US$768.78M. This suggests that, Endo International has historically performed better than recently, despite the fact that it seems like earnings are now heading back in the right direction again.
We can further evaluate Endo International’s loss by looking at what the industry has been experiencing over the past few years. Each year, for the past half a decade Endo International’s top-line has risen by a mere 7.89%, on average. The company’s inability to breakeven has been aided by the relatively flat top-line in the past. Viewing growth from a sector-level, the US pharmaceuticals industry has been growing its average earnings by double-digit 13.53% in the prior year, and a more subdued 9.89% over the past five years. This shows that, though Endo International is currently running a loss, it may have gained from industry tailwinds, moving earnings towards to right direction.
What does this mean?
Though Endo International’s past data is helpful, it is only one aspect of my investment thesis. Companies that incur net loss is always hard to forecast what will happen in the future and when. The most insightful step is to examine company-specific issues Endo International may be facing and whether management guidance has dependably been met in the past. You should continue to research Endo International to get a more holistic view of the stock by looking at:
Future Outlook: What are well-informed industry analysts predicting for ENDP’s future growth? Take a look at our free research report of analyst consensus for ENDP’s outlook.
Financial Health: Is ENDP’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.
Endo International plc (ENDPQ) Stock Research Links
Engineer by trade & Swing Trader at Heart!
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
Join Webull today and get up to 75 #FREE stocks!
Get started >> Register with my referral link now>> JOIN HERE NOW
CLICK TO SEE --> Engineer, Design,& Build Packaging Equipment
